Additional Information
Market: NYSE AMEX
Sector: Pharmaceuticals
EPIC: INO
Latest Price: 2.67  (2.69% Ascending)
52-week High: 3.82
52-week Low: 0.54
Market Cap: 641.19M
1 year chart
1 day chart
Inovio Pharmaceuticals
www.inovio.com

Inovio Pharmaceuticals, Inc. is focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases. This next generation of immunotherapies could potentially protect millions of people from debilitation or death from diseases without adequate treatments.

DNA Vaccine maker Inovio to present at multiple conferences

30th Sep 2011, 2:38 pm by Brad Lemaire
DNA Vaccine maker Inovio to present at multiple conferences

Inovio Pharmaceuticals (NYSE:INO), developer of synthetic vaccines against cancers and infectious diseases, reported on Friday that company advisors, collaborators and scientists are scheduled to present at several scientific conferences.

David Weiner will make his presentation on DNA vaccines and T cell responses in humans and animals that induce neutralizing immune responses, at the Marriott Waterfront Hotel on Oct. 2, Seattle.

A day after, product development scientist, Matt Morrow, will make a presentation on induction of Human papillomavirus (HPV) specific CTLs, or killer T cells, in humans after DNA immunization. 

Further, a second conference called Cancer Immunotherapy is taking place at the Millennium Broadway and Conference Centre, in New York.

Mark Bagarazzi, Chief Medical Officer, will make his presentation on Oct. 6 on the topic of delivering potent and durable immune responses with HPV 16 and 18, as well as DNA vaccines through electroporation.  

Bagarazzi is scheduled to make another lecture at the World Vaccine Congress on Oct. 11 in France where he will discuss the future of "Holy Grail" vaccines.

A skin vaccination summit will take place on Oct. 12 to 14 at the Kellogg Conference Hotel in Washington, D.C. 

Kate Broderick of research and development is set to make her presentation on Oct. 13 and will talk about DNA delivery to skin is enhanced by next-generation devices that target dermal tissue. Niranjan Sardesai also from research and development will talk about vaccines for emerging infectious diseases, making his presentation on Oct. 14.

Finally, the fifth conference at Providence, Rhode Island and is scheduled for Oct. 17 to 19. 

Niranjan Sardesai of research and development will present at the Vaccines Renaissance Conference discussing induction of HPV specific CTLs in humans after DNA immunotherapy on Oct. 18.

Blue Bell, Pennsylvania-based Inovio Pharmaceutical, formerly Inovio Biomedical Corp, is developing next generation vaccines, known as DNA-based vaccines, to treat and prevent cancers and infectious diseases. Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here